Annual Report for 2017 Initiator Pharma A/S

Initiators Pharma’s Annual Report for 2017 is from today available on the company’s website

Initiators Pharma’s Annual Report for 2017 is from today available on the company’s website,

http://initiatorpharma.com/investors/financial-reports/

For further information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO

Telephone: +45 6126 0035

E-mail: ceo@initiatorpharma.com

About Initiator Pharma

Initiator Pharma is a pharmaceutical company based in Aarhus, Denmark, spun off from Saniona AB (listed on Nasdaq Stockholm First North Premier). The company’s primary focus is the drug candidate IPED2015 which constitutes a new treatment method for the indication of erectile dysfunction (ED), that is, the inability of a man to achieve and maintain an erection and thus be able to complete sexual intercourse. Initiator Pharma’s new method of treatment with IPED2015 intends to address the large group of patients suffering from erectile dysfunction and who are resistant to current therapies.